hexameric CD95 ligand (APO010) / Allarity Therap, Valerio Therap - LARVOL DELTA

International Registry of thyroid cancer in Latin American (CaTaLiNA): epidemiology, clinical and follow-up study protocol in Latin American countries during the period 2023-2028. (PubMed, BMJ Open) - "This study protocol was approved by Comité de Ética de Investigación en Seres Humanos de la Universidad San Francisco de Quito USFQ 'CEISH-USFQ' APO-010-2023-CEIHS-USFQ Oficio No. 161-2023-CA-23030M-CEISH-USFQ. Results will be disseminated via peer-reviewed publications."

Journal • Endocrine Cancer • Endocrine Disorders • Oncology • Otorhinolaryngology • Solid Tumor • Thyroid Gland Carcinoma

Characterization of resistance to a recombinant hexameric Fas-ligand (APO010) in human cancer cell lines. (PubMed, Exp Hematol) - No abstract available

Journal • Preclinical • Oncology • FASLG

Safety and Pharmacokinetics of Rising Doses of APO010 in Relapsed/Refractory Multiple Myeloma Patients Selected by DRP (clinicaltrials.gov) - P1/2; N=1; Terminated; Sponsor: Oncology Venture; N=35 ➔ 1; Recruiting ➔ Terminated; The study was terminated early due to sponsors decision

Enrollment change • Trial termination

Prevention of Acute Graft Versus Host Disease in Patients Undergoing Allogeneic ApoGraft Stem Cell Transplantation (clinicaltrials.gov) - P1/2; N=12; Recruiting; Sponsor: Cellect Biotechnology; Trial completion date: Dec 2019 ➔ Jul 2020; Trial primary completion date: Dec 2019 ➔ Jul 2020

Clinical • Trial completion date • Trial primary completion date

Safety and Pharmacokinetics of Rising Doses of APO010 in Relapsed/Refractory Multiple Myeloma Patients Selected by DRP (clinicaltrials.gov) - P1/2; N=35; Recruiting; Sponsor: Oncology Venture; Trial completion date: Jan 2019 ➔ Jan 2020; Trial primary completion date: Dec 2018 ➔ Dec 2019

Clinical • Trial completion date • Trial primary completion date